Navigation Links
Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
Date:11/10/2010

COLUMBIA, Md., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it has changed  the date and time to discuss third quarter 2010 results due to the Veteran's Day Holiday on November 11, 2010.  The SEC's EDGAR service will not receive, process or accept filings on November 11 because of the Veteran's Day Holiday, and Celsion is rescheduling its third quarter conference call for 3:00 p.m. ET on Monday, November 15, 2010 to enable it to allow for its quarterly report on Form 10-Q for the quarter ended September 30, 2010 and current report on Form 8-K to be filed and furnished to the SEC, respectively, and disseminated to investors in advance of the conference call in compliance with applicable SEC regulations.  To participate in the call, interested parties may dial 1-888-218-8172 (Toll free U.S./Canada) or 1-913-312-9313 (International/Toll) and use Conference ID:  4428936 to register ten minutes before the call is scheduled to begin.  The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Monday, November 15, 2010 at 6 p.m. ET and will remain available until Monday, November 22, 2010.  The replay can be accessed at 1-877-870-5176 (Toll Free U.S./Canada) or 1-858-384-5517 (International/Toll) using Conference ID:  4428936.  The call will also be available on the Company's website, http://www.celsion.com for 30 days after 5:00 p.m. ET on Monday, November 15, 2010.

About Celsion Corporation Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems.  Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Philips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers.  Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website:  http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

ThermoDox® is a registered trademark of Celsion Corporation.  Investor Contact:Marcy NanusThe Trout Group646.378.2927 or mnanus@troutgroup.com
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
3. Kendle Announces Third Quarter 2010 Results
4. Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors
5. Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
6. Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
7. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
8. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
9. Hoya Announces Second Quarter Financial Results
10. Metamark Genetics, Inc. Announces New Chief Executive Officer
11. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... program for the development of future natural products for crop ... and development center in Israel and ... Stockton has a variety of products adapted to ... in more than 35 counties worldwide. ... product Timorex Gold ® is used to control a ...
(Date:2/6/2016)... ... February 06, 2016 , ... The Center for Excellence in Education ... high school teachers on Wednesday February 10, 2016. This Bite of Science session, ... of Conservation, located at 1500 Remount Road in Front Royal, VA from 5:00 p.m. ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):